Avior Wealth Management LLC Reduces Stake in Ascendis Pharma A/S (NASDAQ:ASND)

Avior Wealth Management LLC decreased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 7.9% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 7,561 shares of the biotechnology company’s stock after selling 651 shares during the period. Avior Wealth Management LLC’s holdings in Ascendis Pharma A/S were worth $1,041,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Loomis Sayles & Co. L P increased its stake in Ascendis Pharma A/S by 35.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after acquiring an additional 48,120 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Ascendis Pharma A/S by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after acquiring an additional 4,338 shares during the last quarter. Valence8 US LP bought a new position in Ascendis Pharma A/S in the 3rd quarter worth about $685,000. Nomura Asset Management Co. Ltd. increased its stake in Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock worth $2,688,000 after acquiring an additional 5,371 shares during the last quarter. Finally, Maven Securities LTD bought a new position in Ascendis Pharma A/S in the 3rd quarter worth about $7,466,000.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $128.20 on Friday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The stock has a 50 day simple moving average of $133.28 and a two-hundred day simple moving average of $133.25. The stock has a market cap of $7.78 billion, a P/E ratio of -15.87 and a beta of 0.65.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective on the stock. Oppenheimer reduced their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and an average price target of $192.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.